AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2862814 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 5 mg
Number of subjects: 12
Study 2862814 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 12
Study 2862814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29873684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin added to 5-FU-based chemoradiotherapy and adjuvant chemotherapy in patients aged <60 years
Number of subjects: 1232
Study 29873684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin added to 5-FU-based chemoradiotherapy and adjuvant chemotherapy in patients aged 40-70 years
Number of subjects: 1232
Study 29873684 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients aged ≥70 years)
Number of subjects: 1232
Study 24187121 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Healthy Children (BHC) intervention including Parents as Teachers, child-parent psychotherapy, and interpersonal psychotherapy as needed.
Number of subjects: 497
Study 24187121 — intervention group
Group type: COMPARATOR
Intervention: Screening and referral to community services only (control group).
Number of subjects: 497
Study 21435238 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth on a birth seat
Number of subjects: 1002
Study 21435238 — intervention group
Group type: COMPARATOR
Intervention: Any other position (control group)
Number of subjects: 1002
Study 19393850 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Integrol(R)) 10 mg tablet
Number of subjects: 24
Study 19393850 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Zyprexa(R)) 10 mg tablet
Number of subjects: 24
Study 17596577 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-adaptive design
Number of subjects: 0
Study 17596577 — intervention group
Group type: COMPARATOR
Intervention: Traditional trial design
Number of subjects: 0
Study 15325831 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 18325
Study 15325831 — intervention group
Group type: COMPARATOR
Intervention: non-steroidal anti-inflammatory drugs (naproxen 500 mg twice daily or ibuprofen 800 mg three times daily)
Number of subjects: 18325
Study 15325831 — intervention group
Group type: COMPARATOR
Intervention: non-steroidal anti-inflammatory drugs
Number of subjects: 18325
Study 11215327 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release dihydrocodeine (DHC) 60 mg
Number of subjects: 12
Study 11215327 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release dihydrocodeine (DHC) 120 mg
Number of subjects: 12
Study 11215327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9605982 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen (Remune)
Number of subjects: 0
Study 9605982 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 0
Study 7871098 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g/kg ethanol
Number of subjects: 27
Study 7871098 — intervention group
Group type: COMPARATOR
Intervention: 20 mg diazepam
Number of subjects: 27
Study 2899329 — intervention group
Group type: EXPERIMENTAL
Intervention: oxazolam
Number of subjects: 40
Study 2899329 — intervention group
Group type: COMPARATOR
Intervention: chlorprothixene
Number of subjects: 40
Study 31678559 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK Xtra (30 mW/cm2, 90 seconds with continuous ultraviolet‐A)
Number of subjects: 26
Study 31678559 — intervention group
Group type: COMPARATOR
Intervention: convLASIK
Number of subjects: 26
Study 31678559 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK Xtra
Number of subjects: 26
Study 30592963 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-6 regimen with L-carnosine (500 mg daily)
Number of subjects: 65
Study 30592963 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-6 regimen without L-carnosine
Number of subjects: 65
Study 28477428 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor 150 mg alone (study A)
Number of subjects: 12
Study 28477428 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor 150 mg plus ritonavir 50 mg daily (study B)
Number of subjects: 12
Study 28477428 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor 150 mg plus ritonavir 50 mg daily after two weeks of ritonavir 50 mg daily (study C)
Number of subjects: 12
Study 24779558 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional Identity Development Program (10 sessions, implemented once a week)
Number of subjects: 63
Study 24779558 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study 23680943 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 14
Study 23680943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20868630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 24
Study 20868630 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 24
Study 20868630 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BOLD responses in left fusiform gyrus
Number of subjects: 24
Study 20868630 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BOLD responses in right rolandic operculum
Number of subjects: 24
Study 18435837 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC) for 15 minutes prior to and throughout heel lance procedure
Number of subjects: 61
Study 18435837 — intervention group
Group type: COMPARATOR
Intervention: Control condition (prone position swaddled in a blanket in the incubator)
Number of subjects: 61
Study 21667097 — intervention group
Group type: COMPARATOR
Intervention: Paroxysmal AF (n = 63)
Number of subjects: 115
Study 21667097 — intervention group
Group type: COMPARATOR
Intervention: Persistent AF (n = 34)
Number of subjects: 115
Study 21667097 — intervention group
Group type: COMPARATOR
Intervention: Long-term persistent AF (n = 18)
Number of subjects: 115
Study 21667097 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall follow-up after ablative treatment
Number of subjects: 115
Study 16131698 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 or 1000 mg/d for 2 weeks)
Number of subjects: 12
Study 16131698 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study 16131698 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 12
Study 11881902 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR) in a reproduction task
Number of subjects: 0
Study 11881902 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR) in a production task
Number of subjects: 0
Study 9553213 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional application of opioids via pump systems
Number of subjects: 0
Study 7666815 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - either peroral or transdermal 17‐beta‐oestradiol with cyclic addition of dydrogesterone or 2.5 mg Tibolone (Org OD 14) in a daily peroral dose
Number of subjects: 105
Study 7666815 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 105
Study 2635446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxiphyllin
Number of subjects: 36
Study 2635446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 326302 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 8
Study 326302 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 8
Study 326302 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg) and Acetazolamide (500 mg) in combination
Number of subjects: 8
Study 326302 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (inert tablets)
Number of subjects: 8
Study 30592724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymizer
Number of subjects: 24
Study 30592724 — intervention group
Group type: COMPARATOR
Intervention: Conventional Nasal Cannula (CNC)
Number of subjects: 24
Study 27866187 — intervention group
Group type: COMPARATOR
Intervention: Whey protein supplementation (24 g PRO)
Number of subjects: 17
Study 27866187 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein plus creatine supplementation (24 g PRO + 5 g creatine)
Number of subjects: 17
Study 25001543 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-communicatively cued goal-directed intention understanding in children with ASD
Number of subjects: 0
Study 25001543 — intervention group
Group type: EXPERIMENTAL
Intervention: Object-oriented intention understanding in children with ASD
Number of subjects: 0
Study 25001543 — intervention group
Group type: COMPARATOR
Intervention: Attention to the experimenter's face during trials
Number of subjects: 0
Study 22944053 — intervention group
Group type: EXPERIMENTAL
Intervention: tianmaixiaoke tablet 240 mg bid for 24 weeks
Number of subjects: 84
Study 22944053 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin 100 mg qd for 24 weeks
Number of subjects: 84
Study 21115586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 1804
Study 21115586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1804
Study 17702654 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐length Lycra stinger suit (S)
Number of subjects: 0
Study 17702654 — intervention group
Group type: COMPARATOR
Intervention: Normal swimwear (SW)
Number of subjects: 0
Study 16417772 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingqiao Capsule (QQC), 5 capsules each time, 3 times a day for 10-14 days
Number of subjects: 90
Study 16417772 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor capsules, 0.5 g each time for adults, 3 times a day, or 20 mg/(kg.d) for children, for 10-14 days
Number of subjects: 90
Study 16417772 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingqiao Capsule (QQC)
Number of subjects: 90
Study 16417772 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor capsules
Number of subjects: 90
Study 12854076 — intervention group
Group type: EXPERIMENTAL
Intervention: CM235 gp120 (25, 50, or 100 microg)
Number of subjects: 370
Study 12854076 — intervention group
Group type: EXPERIMENTAL
Intervention: SF2 gp120 (0, 25, or 50 microg)
Number of subjects: 370
Study 12854076 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CM235 and SF2 gp120 vaccines
Number of subjects: 370
Study 12854076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 10097029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour routine exercise
Number of subjects: 21
Study 10097029 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising students)
Number of subjects: 21
Study 8548508 — intervention group
Group type: COMPARATOR
Intervention: H-reflex facilitation during response period
Number of subjects: 40
Study 8548508 — intervention group
Group type: COMPARATOR
Intervention: Achilles tendon reflex facilitation during response period
Number of subjects: 40
Study 2016618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (30 mg/m2 orally day 1) and Prednisone (80 mg orally days 1 to 5) administered every 2 weeks (C + P)
Number of subjects: 122
Study 2016618 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (300 mg/m2 orally days 1 to 5), Vincristine (1.4 mg/m2 intravenously [IV] day 1), and Prednisone (100 mg/m2 orally days 1 to 5) given every 3 weeks (CVP)
Number of subjects: 122
Study 2016618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil and Prednisone (C + P)
Number of subjects: 122
Study 2016618 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, Vincristine, and Prednisone (CVP)
Number of subjects: 122
Study 7036711 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 11
Study 7036711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30856691 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 60
Study 30856691 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival Scaling
Number of subjects: 60
Study 30856691 — intervention group
Group type: COMPARATOR
Intervention: Control (no periodontal treatment)
Number of subjects: 60
Study 30856691 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 60
Study 29912799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (5-15 mg/d)
Number of subjects: 46
Study 29912799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 27344828 — intervention group
Group type: EXPERIMENTAL
Intervention: Float needle therapy combined with reperfusion activity
Number of subjects: 35
Study 27344828 — intervention group
Group type: COMPARATOR
Intervention: Simple float needle therapy
Number of subjects: 35
Study 24939425 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfusion of low-dose GLP-1 and glucagon
Number of subjects: 13
Study 24939425 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 alone
Number of subjects: 13
Study 24939425 — intervention group
Group type: COMPARATOR
Intervention: Glucagon alone
Number of subjects: 13
Study 24939425 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfusion of GLP-1 and glucagon
Number of subjects: 13
Study 24939425 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 with glucagon
Number of subjects: 13
Study 22063233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Number of subjects: 93
Study 22063233 — intervention group
Group type: COMPARATOR
Intervention: Compression stockings
Number of subjects: 93
Study 22063233 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene bypass
Number of subjects: 93
Study 22063233 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bypass
Number of subjects: 93
Study 20502467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support prescribed to patients with overt malnutrition (n=191)
Number of subjects: 1583
Study 20502467 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of weight during hospital stay
Number of subjects: 1583
Study 20502467 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI calculation
Number of subjects: 1583
Study 20502467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Risk Screening 2002 tool
Number of subjects: 1583
Study 17561350 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane treatment arm
Number of subjects: 0
Study 17561350 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-based regimens
Number of subjects: 0
Study 16205932 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 10 mg Si/day for 20 weeks
Number of subjects: 50
Study 16205932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12029208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for severity scores
Number of subjects: 48
Study 12029208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement on overall impression for Alzheimer's pattern
Number of subjects: 48
Study 12029208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement on overall impression for heterogeneous pattern
Number of subjects: 48
Study 12029208 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for overall impression for Alzheimer's pattern
Number of subjects: 48
Study 12029208 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for overall impression for heterogeneous and normal patterns
Number of subjects: 48
Study 12029208 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement as reflected in percent agreement
Number of subjects: 48
Study 12885182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 mcg/kg (group F)
Number of subjects: 26
Study 12885182 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 10 mcg/kg plus etomidate 0.2 mg/kg (group EF)
Number of subjects: 26
Study 9654535 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of lamivudine
Number of subjects: 358
Study 9654535 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of lamivudine
Number of subjects: 358
Study 9654535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 8135383 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA insertion with cuff partially inflated
Number of subjects: 122
Study 8135383 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine topical solution
Number of subjects: 122
Study 8135383 — intervention group
Group type: COMPARATOR
Intervention: Standard deflated method
Number of subjects: 122
Study 8135383 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Y sterile lubricating jelly
Number of subjects: 122
Study 8135383 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 122
Study 2800985 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine
Number of subjects: 36
Study 2800985 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 36
Study 2800985 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 36
Study 2800985 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline containing mepivacaine
Number of subjects: 36
Study 2800985 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline containing bupivacaine
Number of subjects: 36
Study 105441 — intervention group
Group type: EXPERIMENTAL
Intervention: Superfractionation treatment
Number of subjects: 602
Study 105441 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation schemes
Number of subjects: 602
Study 30589514 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS pathway with ketorolac and pregabalin
Number of subjects: 62
Study 30589514 — intervention group
Group type: COMPARATOR
Intervention: Standard of care plus placebo
Number of subjects: 62
Study 28752209 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid (ERN) 2 g/day for 8 weeks
Number of subjects: 8
Study 26040944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying-flat (0°) head positioning
Number of subjects: 16800
Study 26040944 — intervention group
Group type: COMPARATOR
Intervention: Sitting-up (≥ 30°) head positioning
Number of subjects: 16800
Study 23839169 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry (VBM) analysis
Number of subjects: 50
Study 23839169 — intervention group
Group type: EXPERIMENTAL
Intervention: Tract-based spatial statistics (TBSS) analysis
Number of subjects: 50
Study 21756364 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pirfenidone (1800 mg/day)
Number of subjects: 267
Study 21756364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pirfenidone (1200 mg/day)
Number of subjects: 267
Study 21756364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 18803561 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced ventricular tachycardias (VTs)
Number of subjects: 72
Study 16735334 — intervention group
Group type: EXPERIMENTAL
Intervention: Curtains treated with lambdacyhalothrin and water treatment with pyriproxyfen chips in Veracruz
Number of subjects: 10049
Study 16735334 — intervention group
Group type: EXPERIMENTAL
Intervention: Curtains treated with longlasting deltamethrin (PermaNet) plus water jar covers in Trujillo
Number of subjects: 10049
Study 16735334 — intervention group
Group type: COMPARATOR
Intervention: Control group in Veracruz
Number of subjects: 10049
Study 16735334 — intervention group
Group type: COMPARATOR
Intervention: Control group in Trujillo
Number of subjects: 10049
Study 15332694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for adverse drug events (ADEs)
Number of subjects: 543
Study 15332694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for preventable ADEs
Number of subjects: 543
Study 15332694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for potential ADEs
Number of subjects: 543
Study 15332694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for life-threatening ADEs
Number of subjects: 543
Study 15332694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for serious ADEs
Number of subjects: 543
Study 15332694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for significant ADEs
Number of subjects: 543
Study 15332694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for drug classes associated with ADEs
Number of subjects: 543
Study 11319565 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-person perspective
Number of subjects: 0
Study 11319565 — intervention group
Group type: COMPARATOR
Intervention: First-person perspective
Number of subjects: 0
Study 9283534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal CPAP plus optimal medical therapy (n = 9)
Number of subjects: 17
Study 9283534 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone (n = 8)
Number of subjects: 17
Study 8099549 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 500 micrograms.kg‐1 over 1 min followed by 100 micrograms.kg‐1.min‐1
Number of subjects: 14
Study 8099549 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 3324520 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuprol (3 X 200 mg t. i. d.)
Number of subjects: 10
Study 3324520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3324520 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuprol
Number of subjects: 10
Study 30587618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin split (GCsplit)
Number of subjects: 41
Study 30587618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Carboplatin (GCarbo)
Number of subjects: 41
Study 30587618 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/Cisplatin (GC)
Number of subjects: 41
Study 28862770 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucosamine (GS) + hyaluronic acid (HA) injection
Number of subjects: 136
Study 28862770 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo + hyaluronic acid (HA) injection
Number of subjects: 136
Study 26777773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) as an adjunct to usual care (medication)
Number of subjects: 248